BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11180765)

  • 21. An overview of HER2.
    Lohrisch C; Piccart M
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):3-11. PubMed ID: 11774200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
    Mihály Z; Gyõrffy B
    Magy Onkol; 2013 Sep; 57(3):147-56. PubMed ID: 24107820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the biologic and clinical complexities of HER2.
    Park JW; Neve RM; Szollosi J; Benz CC
    Clin Breast Cancer; 2008 Oct; 8(5):392-401. PubMed ID: 18952552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapy in breast cancer: the HER-2/neu gene and protein.
    Ross JS; Fletcher JA; Bloom KJ; Linette GP; Stec J; Symmans WF; Pusztai L; Hortobagyi GN
    Mol Cell Proteomics; 2004 Apr; 3(4):379-98. PubMed ID: 14762215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tykerb for breast cancer].
    Suzuki Y; Saito Y; Okamura T; Tokuda Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting HER2 for the treatment of breast cancer.
    Rimawi MF; Schiff R; Osborne CK
    Annu Rev Med; 2015; 66():111-28. PubMed ID: 25587647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
    Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
    J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
    Lu Y; Zi X; Zhao Y; Pollak M
    Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.